Myosin modulators: Emerging approaches for the treatment of cardiomyopathies and heart failure

Sharlene M. Day, Jil C. Tardiff, E. Michael Ostap

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Myosin modulators are a novel class of pharmaceutical agents that are being developed to treat patients with a range of cardiomyopathies. The therapeutic goal of these drugs is to target cardiac myosins directly to modulate contractility and cardiac power output to alleviate symptoms that lead to heart failure and arrhythmias, without altering calcium signaling. In this Review, we discuss two classes of drugs that have been developed to either activate (omecamtiv mecarbil) or inhibit (mavacamten) cardiac contractility by binding to β-cardiac myosin (MYH7). We discuss progress in understanding the mechanisms by which the drugs alter myosin mechanochemistry, and we provide an appraisal of the results from clinical trials of these drugs, with consideration for the importance of disease heterogeneity and genetic etiology for predicting treatment benefit.

Original languageEnglish (US)
Article numbere148557
JournalJournal of Clinical Investigation
Volume132
Issue number5
DOIs
StatePublished - Mar 1 2022

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Myosin modulators: Emerging approaches for the treatment of cardiomyopathies and heart failure'. Together they form a unique fingerprint.

Cite this